Elranatamab: all 37 studies that test it
Page 1 of 1. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07901868Phase 2
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingNCT07881835Phase 4
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot yet recruitingNCT07788469Not applicable
- HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVRecruitingNCT07647432Phase 1
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07637578Phase 2
- Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) AmyloidosisNot yet recruitingNCT07524634Phase 2
- A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"RecruitingNCT07382739Phase 2
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple MyelomaNot yet recruitingNCT07247097Phase 2
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingNCT06997081Phase 2
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06988488Phase 1/2
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed MyelomaRecruitingNCT06947083Phase 2
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingNCT06918002Phase 3
- ELISA in Relapsed/Refractory MMRecruitingNCT06832865Phase 2
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaRecruitingNCT06799026Phase 1
- Elranatamab in Relapsed/Refractory Multiple MyelomaRecruitingNCT06711705Phase 2
- Elranatamab in Patients With Relapsed or Refractory AL AmyloidosisRecruitingNCT06569147Phase 1/2
- Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaRecruitingNCT06421675Phase 2
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingNCT06207799Phase 2
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingNCT06152575Phase 3
- Elranatamab in R/R Multiple MyelomaRecruitingNCT06138275Phase 2
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Phase 4
- Self-administration of Subcutaneous Elranatamab in the Patients' Homes.RecruitingNCT06015542Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)RecruitingNCT05927571Phase 1
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Phase 3
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Phase 3
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedNCT05090566Phase 2Results posted
- A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to TreatmentCompletedNCT05014412Phase 2Results posted
- MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple MyelomaCompletedNCT04798586Phase 1Results posted
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbCompletedNCT04649359Phase 2Results posted
- PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaCompletedNCT03269136Phase 1Results posted
- Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Active, not recruitingNCT06931704Phase 2
- Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug ClassesActive, not recruitingNCT06282978Phase 2
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Active, not recruitingNCT06215118Phase 1
- Use of Elranatamab in Patients With High-risk Smoldering Multiple MyelomaActive, not recruitingNCT06183489Phase 2
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingNCT05317416Phase 3